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Objectives: The primary aim of the study was to estimate costs of treatment for the 
first year after renal transplantation from the perspective of health insurance organi-
zations in Iran. MethOds: An Excel-based and a Monte Carlo model were developed 
to determine the treatment costs of current clinical practice in renal transplantation 
therapy (RTT). Inputs were derived from Ministry of Health and insurance organiza-
tions’ database, hospital and pharmacy records, clinical trials and local and interna-
tional literature. According to the model, there were almost 17,000 patients receiving 
RTT in Iran, out of which about 2,200 patients underwent the operation within the 
study year (2011- 2012; n= 2200). Results: The estimated first year total treatment 
cost after renal transplantation was almost $14,000,000. These costs corresponded to 
annual total cost per patient of almost $6500 for the payers. cOnclusiOns: Renal 
transplantation therapy is almost fully reimbursed by government in Iran. However, 
regarding new expensive medicines, cost of medical expenditure is rapidly growing 
and becoming quite unaffordable for the government; therefore, out-of-pocket (OOP) 
payments are dramatically increasing over time. In order to improve reimbursement 
policy making under pressure of current budget constraints, the present study is 
providing decision makers with practical tools make them possible to easily compare 
budgetary impact of the current therapy strategy with the future financial conse-
quences of purchasing newly proposed medicines. In other words having estimation 
of the current budget spending on RTT would help policy makers in making efficient 
resource allocation and decrease quite high OOP expenditures.
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Objectives: To evaluate resource utilisation for subjects with overactive 
bladder (OAB) syndrome who are managed with the commonly prescribed oral 
medications: solifenacin succinate, tolterodine tartrate, or trospium chloride from 
the payer perspective. MethOds: Data were abstracted from medical records for 
qualified subjects who were ≥ 18 years, with a diagnosis for OAB (at least one of the 
following: urgency, frequency with or without urgency incontinence) on or before 
December 31, 2010. Subjects must have been on one of the study medications for at 
least 3 months and have at least 12 months of medical records available. The study 
was approved by local ethics committees and all data provided was anonymised. 
Medication costs for Germany are reported for 2013 € . Results: A total of 136 of 
229 subjects were included for the German analysis. The remaining subjects were 
from the Czech Republic to be reported elsewhere. Top 3 reasons for exclusion from 
Germany include: primary diagnosis of urinary tract infection, urologic surgery 
within 6 months of the data collection, and diabetic neuropathy. The annual overall 
mean cost for office visits, specialist visits, investigations, other treatments, medica-
tions and incontinence pad use with solifenacin (5,10mg/day) (N= 60), trospium (IR 
and ER maximum dose of 60mg/day) (N= 51), and tolterodine (IR 2, 4mg/day and ER 
4mg/day) (N= 25), were € 1,059.31, € 1,247.76, and € 1,626.01, respectively. Incontinence 
pad use for weekly frequency with solifenacin, trospium, and tolterodine was, 17.34, 
19.51 and 20.35, respectively. Overall satisfaction with medication as perceived by 
the clinician (very satisfied, satisfied, neutral, dissatisfied, very dissatisfied) for very 
satisfied and satisfied was 97%, 86%, 100%, for solifenacin, trospium, tolterodine, 
respectively. cOnclusiOns: Solifenacin had the lowest annual cost-in-use com-
pared to other study drug annual cost. This was corroborated in part by the lowest 
incontinence pad use for solifenacin compared to trospium and tolterodine and 
the high treatment satisfaction.
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Objectives: Urgency urinary incontinence (UUI) has a substantial impact on 
patients’ QOL and well-being, and may pose a substantial economic burden on 
patients and health insurers. We assessed the cost and cost-effectiveness of four 
conservative treatment modalities for UUI in Israel. MethOds: A total of 164 
women were randomly allocated to one of four interventions: drug therapy (DT), 
bladder training (BT), pelvic floor muscle-training (PFMT), and combined pelvic floor 
rehabilitation (CPFR) and were followed over a period of 12-months. Resource utili-
zation including physician encounters, dispensed prescriptions, physical therapist 
treatment and any other medical services was estimated for each study participant. 
We also estimated the women’s self-reported utilizations of pads, laundry and new 
underwear. Total costs were calculated by multiplying the volumes of resource uti-
lization by the corresponding unit-prices. We used the bootstrap method to report 
bias-corrected confidence-intervals of cost estimates. Utility weights were elicited 
using the EQ-5D questionnaire at baseline, 3-months and 12-months of follow-
up. Results: Women in all four treatment groups showed improvements in QOL 
from baseline to 12-months (DT:0.87 - 0.93, BT:0.85 to 0.89, PFMT:0.82 - 0.84, CPFR: 
0.82 to 0.86). Changes in QOL summary scores from study enrollment and end of 
follow-up were estimated after correction for potential baseline differences, and 
were not statistically different among study groups. The mean total cost was some-
what lower for the DT group participants ($1,460), as compared with the three other 
interventions (range: $1,760-$1,990). These differences, however, were not statisti-
cally significant. The mean monthly personal costs were significantly reduced from 
baseline to 12-months of follow-up in all treatment groups. cOnclusiOns: The 
four treatment modalities for treating UUI were equally effective and associated 
of hospitalizations with ICD-9 diagnosis codes of CKD and End Stage Renal Disease 
(ESRD). The annual number of hospitalizations for specific diagnosis was obtained 
from AHRQ’s National In-patient Sample (NIS) databases of 2005-2009. Data was 
also analyzed for length of stay (LOS), charges and cost of hospitalization. Results: 
During the last five years the number of hospitalizations with diagnosis of CKD and 
ESRD has increased 4.1 and 4.6 fold, respectively. In 2009, an estimated 1,634,422 
and 931,641 hospitalizations were with diagnosis of CKD and ESRD respectively. The 
mean LOS for patients with CKD increased from 4.9 to 5.5 days between2005-2009. 
The mean LOS for patients with ESRD has remained steady at ~6 days between 2005-
2009. The cost of hospitalization with diagnosis of CKD has increased 31% between 
2005-2009. The cost of hospitalization with diagnosis of ESRD has increased 21% 
between 2005-2009. In 2009, the mean cost of hospitalization for patients with CKD 
and ESRD was $11,209 and $21,358, respectively. cOnclusiOns: Hospitalizations 
due to CKD and ESRD have significantly increased during the last five years. There 
is a need for prevention, treatment, and disease management programs to lower 
the medical and socioeconomic burden of this disease.
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Objectives: To examine the economic burden and health care utilizations of 
patients diagnosed with chronic kidney disease (CKD) in the U.S. veteran popula-
tion. MethOds: A retrospective database analysis was performed using the Veterans 
Health Administration (VHA) Medical SAS datasets (01OCT2008-30SEP2012). Patients 
diagnosed with CKD were identified using International Classification of Disease 9th 
Revision Clinical Modification (ICD-9-CM) diagnosis codes 585.xx, 250.4xx, 791.0x, 583.
xx, and 403.xx. The first diagnosis date was designated as the index date. A group of 
non-CKD patients of the same age, region, gender and index year were identified and 
matched on baseline Charlson Comorbidity Index (CCI) as the comparison group with 
a randomly chosen index date to minimize selection bias. Patients in both groups 
were required to be at least 18 years old, and have continuous health plan benefits 
1 year before and 1 year after the index date. One-to-one propensity score match-
ing was used to compare the health care costs and utilizations during the follow-up 
period between the CKD and comparison groups, adjusted for baseline demographic 
and clinical characteristics. Results: A total of 477,078 patients were identified for 
the CKD cohort and the comparison cohort. After 1:1 matching, 155,324 of patients 
were matched from each group, and the baseline characteristics were well-balanced. 
CKD Patients incurred higher health care utilizations in inpatient (17.00% vs. 2.84%, 
p< 0.01), emergency room (17.81% vs. 6.64%, p< 0.01), physician office (99.28% vs. 67.92%, 
p< 0.01), outpatient (99.36% vs. 68.69%, p< 0.01), and pharmacy visits (91.16% vs. 72.61%, 
p< 0.01). The CKD group also had higher patient expenditures in inpatient ($6,228 vs. 
$802, p< 0.01), emergency room ($194 vs. $62, p< 0.01), physician office ($3,287 vs. $1,516, 
p< 0.01), outpatient ($3,788 vs. $1,715) and pharmacy ($848 vs. $490, p< 0.01) than 
patients in the comparison group. cOnclusiOns: CKD patients had a significantly 
higher burden of illness compared to a similar comparison group of non-CKD patients.
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Objectives: Itchy and dry skin, symptoms of pruritus, are commonly reported by 
patients with end-stage renal disease (ESRD). Previous analyses of a large dialysis 
organization (LDO) suggested that these symptoms are associated with decreased 
quality of life and poorer health outcomes. As a result, these patients may represent 
a higher economic burden to payers. This retrospective cohort study compared direct 
health care resource utilization (HRU) and costs associated with varying degrees of 
self-reported itchiness/dryness skin severity. MethOds: Adult patient data (≥ 18 
years old) from the 2009 United States Renal Disease System (USRDS) dataset were 
combined with corresponding Kidney Disease Quality of Life (KDQOL) survey data 
obtained between January to September 2009, at an LDO. Patients were included if 
they had answered KDQOL itchiness/dryness questions, had KDQOL assessments ≥ 
3 months after starting dialysis, and had Medicare as their primary payer. Patients 
were grouped by their itchiness/dryness severity. All HRU and cost outcomes were 
described over a 3-6 month follow-up period post-KDQOL survey. Patients were 
censored for death, transplant, change in treatment modality, discontinued treat-
ment, or loss of observation during the follow-up period. Results: Study popula-
tion included 1,387 patients. HRU analyses of itchiness showed increased rate of 
hospitalizations (42.5% vs. 28.4%) for patients who were extremely bothered versus 
not bothered by itch. Similar results were observed for dryness (34.3% vs. 27.5%) 
and combined itchiness and dryness (34.2% vs. 28.0%). Extremely bothered patients 
had higher overall health care costs: $33,755 vs. $26,933 for itchiness; $29,801 versus 
$26,321 for dryness; and $29,249 vs. $26,736 for combined itchiness and dryness. 
Dialysis and hospitalization costs contributed the most toward overall health care 
costs. cOnclusiOns: These results suggest an association between increased skin 
itchiness/dryness and increased hospitalizations and health care costs. Additional 
research, adjusting for patient characteristics, is needed to provide more evidence 
for the burden of skin itchiness/dryness in ESRD patients.
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